LPTX
Leap Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
6.61
PEG
0.06
P/B
0.33
P/S
208.80
EV/EBITDA
-0.73
DCF Value
$2.17
FCF Yield
-207.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-9631.6%
Operating Margin
-19649.3%
Net Margin
-8537.8%
ROE
-16.9%
ROA
-10.9%
ROIC
-12.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $62.9M | $0.92 |
| FY 2025 | $0.00 | $4.8M | $0.07 |
| Q3 2025 | $209.0K | $-26.0M | $-0.08 |
| Q2 2025 | $0.00 | $-16.6M | $-0.40 |
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.09
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.